Pemetrexed & Gemcitabine

Phase 2Small molecule

SSwiss Cancer Institute

Pemetrexed & Gemcitabine is one of 49 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

Lenvima

Eisai

Preclinical

6 3

Imjudo

AstraZeneca

Preclinical

5 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Pemetrexed & Gemcitabine

SSwiss Cancer Institute

Phase 2

1 7

Remeron

OOrganon and Co

Preclinical

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatment

1 10

Vidaza

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Not yet recruiting

Metastatic NSCLC

NCT07020065

Clinical

Trials by Indication[1]

Metastatic NSCLC1 trial

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Not yet recruiting·SSwiss Cancer Institute·Phase 2·NCT07020065·156 enrolled

Lung Cancer1 trial

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer

Terminated·—·Phase 2·NCT00545948·31 enrolled

Non-Small Cell Lung Cancer1 trial

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT00509366·101 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pemetrexed & Gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemetrexed & Gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemetrexed & Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Swiss Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSwiss Cancer Institute

Pemetrexed & Gemcitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Metastatic NSCLC1 trial

Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News